CARTProduct Variations
| Product # | Price | Quantity | |
|---|---|---|---|
| VD-AI-0270-0100-100mg | $120 | ||
| VD-AI-0270-1000-1g | $1100 |
Etoposide
$120.00 – $1,100.00
Product Specification
-
Appearance:
White to off-white powder.
-
CAS Number:
33419-42-0, VP-16-213;
-
Cat.number:
VD-AI-0270
-
Formula:
C29H32O13
-
MW:
588.6
-
Purity:
≥97% by HPLC
-
Solubility:
DMSO, dimethyl formamide, ethyl ether or chloroform:MeOH(1:1).
-
Storage:
Store solutions in DMSO at 4°C. Protect from light and moisture.
-
Synonyms:
4-Desmethylepipodophyllotoxin 9-(4,6-O-ethylidene)- β-D-glucopyranoside
-
Size:
100mg, 1g
Description
Antitumor reagent. Topoisomerase II inhibitor (IC50=59.2 µM) . Induces apoptosis by FasL. Activates p53 resulting in upregulated expression of TRAIL-R2 (DR5) and Bak to overcome TRAIL resistance in Bax-deficient human colon carcinoma cancer cells. Slightly soluble in methanol and acetone. For long term storage prepare aliquots and store at -20°C. Induces apoptosis in mouse thymocytes and in HL-60 human leukemia cells.
The podophyllotoxin derivatives VP16-213 and VM26: B.F. Issell; Cancer Chemother. Pharmacol. 7, 73 (1982). Etoposide: four decades of development of a topoisomerase II inhibitor: K.R. Hande; Eur. J. Cancer 34, 1514 (1998). Etoposide sensitivity of human prostatic cancer cell lines PC-3, DU 145 and LNCaP: M. Salido, et al.; Histol. Histopathol. 14, 125 (1999). A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis: C. Mascaux, et al.; Lung Cancer 30, 23 (2000) . Distinct pathways for stimulation of cytochrome c release by etoposide: J.D. Robertson, et al.; J. Biol. Chem. 275, 32438 (2000). Ordering of ceramide formation, caspase activation, and Bax/Bcl-2 expression during etoposide-induced apoptosis in C6 glioma cells: M. Sawada, et al.; Cell Death Differ. 7, 761 (2000). Etoposide-induced apoptosis is not associated with the fas pathway in acute myeloblastic leukemia cells: T. Siitonen, et al.; Leuk. Res. 24, 281 (2000) . Early caspase activation in leukemic cells subject to etoposide-induced G2-M arrest: evidence of commitment to apoptosis rather than mitotic cell death: R.J. Sleiman & B.W. Stewart; Clin. Cancer Res. 6, 3756 (2000). Cell cycle phase specificity in the potentiation of etoposide-induced DNA damage and apoptosis by KN-62, an inhibitor of calcium-calmodulin- dependent enzymes: M. Aoyama, et al.; Biochem Pharmacol 61, 49 (2001). Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis: C.A. Johnson, et al.; J. Biol. Chem. 276, 4539 (2001). In vitro topo II-DNA complex accumulation and cytotoxicity of etoposide in leukaemic cells from patients with acute myelogenous and chronic lymphocytic leukaemia: Y. Wang, et al.; Leuk. Res. 25, 133 (2001)Etoposide: discovery and medicinal chemistry: P. Meresse, et al.; Curr. Med. Chem. 11, 2443 (2004). Etoposide, topoisomerase II and cancer: E.L. Baldwin & N. Osheroff; Curr. Med. Chem. Anticancer Agents 5, 363 (2005).
Reviews
There are no reviews yet.